SRX Global Keeps Bleeding After Reverse Split and Massive Share Overhang — Is There a Floor for This Reinvention Story?
Shares of SRX Global slid another 8.2% to $2.14 on July 20, extending a brutal week that has erased 22% from the stock since July 13. The selloff follows a resale registration filing that could unleash millions of new shares into the market, landing on top of a stock already reeling from an emergency reverse split just two weeks ago. For investors, the question is blunt: does this company have a real business underneath the financial engineering?
A Reverse Split Born Out of Desperation, Not Strategy. SRX Global's stock closed below $0.10 on June 23, triggering an NYSE American noncompliance notice and a trading halt.
The board responded with a 60-for-1 reverse stock split effective July 6, collapsing every 60 shares into one.
Reverse splits are often viewed as a signal of financial distress, which can erode investor confidence — and this one was particularly steep, suggesting deep deterioration in the underlying share price over the prior year.
A Mountain of Shares Waiting to Hit the Market. The company has registered roughly 187.5 million shares (pre-split) for resale by existing holders, including private placement investors, warrant holders, and convertible preferred stockholders.
A March 2026 private placement raised just $4.5 million but issued 22.2 million warrants along with convertible preferred stock. That means early investors received the legal right to sell freely — a classic overhang that pressures the stock even before a single share is dumped.
A Company That Reinvented Itself Overnight. SRX Global completed its acquisition of EMJ Crypto Technologies on June 18, launching what it calls an "AI-driven platform strategy" focused on "high-conviction operating companies and assets." Just months earlier, this was SRx Health Solutions, a pet wellness company with a Canadian subsidiary in restructuring. GuruFocus flagged an Altman Z-Score of 0.3 — deep in the bankruptcy-risk zone.
Listing Compliance Won, But the Market Isn't Convinced. On July 16, NYSE American confirmed SRX Global had regained full listing compliance. Ordinarily good news — yet the stock has fallen every session since, signaling investors see the compliance fix as cosmetic. With convertible securities still outstanding and a vague new business strategy, the dilution math overwhelms any positive headline. At $2.14, the market is pricing in doubt that this pivot produces real cash flows before the next capital raise arrives.